{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:24Z","timestamp":1794047424904,"version":"4.8.0"},"reference-count":27,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative treatment for myelofibrosis. However, the optimal conditioning regimen either with reduced-intensity conditioning (RIC) or myeloablative conditioning (MAC) is not well known. Using the Center for International Blood and Marrow Transplant Research database, we identified adults aged \u226518 years with myelofibrosis undergoing allo-HCT between 2008-2019 and analyzed the outcomes separately in the RIC and MAC cohorts based on the conditioning regimens used. Among 872 eligible patients, 493 underwent allo-HCT using RIC (fludarabine\/ busulfan n=166, fludarabine\/melphalan n=327) and 379 using MAC (fludarabine\/busulfan n=247, busulfan\/cyclophosphamide n=132). In multivariable analysis with RIC, fludarabine\/melphalan was associated with inferior overall survival (hazard ratio [HR]=1.80; 95% confidenec interval [CI]: 1.15-2.81; P=0.009), higher early non-relapse mortality (HR=1.81; 95% CI: 1.12-2.91; P=0.01) and higher acute graft-versus-host disease (GvHD) (grade 2-4 HR=1.45; 95% CI: 1.03-2.03; P=0.03; grade 3-4 HR=2.21; 95%CI: 1.28-3.83; P=0.004) compared to fludarabine\/busulfan. In the MAC setting, busulfan\/cyclophosphamide was associated with a higher acute GvHD (grade 2-4 HR=2.33; 95% CI: 1.67-3.25; P&lt;0.001; grade 3-4 HR=2.31; 95% CI: 1.52-3.52; P&lt;0.001) and inferior GvHD-free relapse-free survival (GRFS) (HR=1.94; 95% CI: 1.49-2.53; P&lt;0.001) as compared to fludarabine\/busulfan. Hence, our study suggests that fludarabine\/busulfan is associated with better outcomes in RIC (better overall survival, lower early non-relapse mortality, lower acute GvHD) and MAC (lower acute GvHD and better GRFS) in myelofibrosis.<\/jats:p>","DOI":"10.3324\/haematol.2022.281958","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T03:57:55Z","timestamp":1675915075000},"page":"1900-1908","source":"Crossref","is-referenced-by-count":35,"title":["Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis"],"prefix":"10.3324","volume":"108","author":[{"given":"Guru Subramanian Guru","family":"Murthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Estrada-Merly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Bilal","family":"Abid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Assal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"Badar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif M.","family":"Badawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ballen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Beitinjaneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Cerny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachariah","family":"DeFilipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel Diaz","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shatha","family":"Farhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar O.","family":"Freytes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Grunwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard C.","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Inamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Jamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Juckett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Kalaycio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell M.","family":"Krem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhold","family":"Munker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant S.","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Ort\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"Van der Poel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Rizzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melhem","family":"Solh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo F.","family":"Verdonck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baldeep","family":"Wirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean A.","family":"Yared","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Oran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Saber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"49623","doi-asserted-by":"crossref","unstructured":"Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021; 96(1):145-162.","DOI":"10.1002\/ajh.26050"},{"key":"49624","doi-asserted-by":"crossref","unstructured":"Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary eview. JAMA Oncol. 2015; 1(1):97-105.","DOI":"10.1001\/jamaoncol.2015.89"},{"key":"49625","doi-asserted-by":"crossref","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9):787-798.","DOI":"10.1056\/NEJMoa1110556"},{"key":"49626","unstructured":"Phelan R, Arora M, Chen M. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides. 2020."},{"key":"49627","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Boluda JC, Pereira A, Kr\u00f6ger N. Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. Leukemia. 2021; 35(1):215-224.","DOI":"10.1038\/s41375-020-0815-z"},{"key":"49628","doi-asserted-by":"crossref","unstructured":"Robin M, de Wreede LC, Wolschke C. Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2019; 104(9):1782-1788.","DOI":"10.3324\/haematol.2018.205211"},{"key":"49629","doi-asserted-by":"crossref","unstructured":"Gowin K, Ballen K, Ahn KW. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020; 4(9):1965-1973.","DOI":"10.1182\/bloodadvances.2019001084"},{"key":"49630","doi-asserted-by":"crossref","unstructured":"Ballen KK, Shrestha S, Sobocinski KA. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2010; 16(3):358-367.","DOI":"10.1016\/j.bbmt.2009.10.025"},{"key":"49631","doi-asserted-by":"crossref","unstructured":"McLornan D, Szydlo R, Koster L. Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019; 25(11):2167-2171.","DOI":"10.1016\/j.bbmt.2019.06.034"},{"key":"49632","doi-asserted-by":"crossref","unstructured":"Gupta V, Malone AK, Hari PN. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2014; 20(1):89-97.","DOI":"10.1016\/j.bbmt.2013.10.018"},{"key":"49633","doi-asserted-by":"crossref","unstructured":"Robin M, Porcher R, Wolschke C. Outcome after transplantation according to reduced-intensity conditioning regimen in patients undergoing transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2016; 22(7):1206-1211.","DOI":"10.1016\/j.bbmt.2016.02.019"},{"key":"49634","doi-asserted-by":"crossref","unstructured":"Jain T, Kunze KL, Temkit M. Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. 2019; 54(2):204-211.","DOI":"10.1038\/s41409-018-0226-1"},{"key":"49635","doi-asserted-by":"crossref","unstructured":"Horowitz M. The role of registries in facilitating clinical research in BMT: examples from the Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant. 2008; 42(Suppl 1):S1-S2.","DOI":"10.1038\/bmt.2008.101"},{"key":"49636","doi-asserted-by":"crossref","unstructured":"Bacigalupo A, Ballen K, Rizzo D. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009; 15(12):1628-1633.","DOI":"10.1016\/j.bbmt.2009.07.004"},{"key":"49637","doi-asserted-by":"crossref","unstructured":"Giralt S, Ballen K, Rizzo D. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009; 15(3):367-369.","DOI":"10.1016\/j.bbmt.2008.12.497"},{"key":"49638","doi-asserted-by":"crossref","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94:496-509.","DOI":"10.1080\/01621459.1999.10474144"},{"key":"49639","doi-asserted-by":"crossref","unstructured":"Commenges D, Andersen PK. Score test of homogeneity for survival data. Lifetime Data Anal. 1995; 1(2):145-156.","DOI":"10.1007\/BF00985764"},{"key":"49640","doi-asserted-by":"crossref","unstructured":"Groenwold RHH, Dekkers OM. Missing data: the impact of what is not there. Eur J Endocrinol. 2020; 183(4):E7-E9.","DOI":"10.1530\/EJE-20-0732"},{"key":"49641","doi-asserted-by":"crossref","unstructured":"Rondelli D, Goldberg JD, Isola L. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 2014; 124(7):1183-1191.","DOI":"10.1182\/blood-2014-04-572545"},{"key":"49642","doi-asserted-by":"crossref","unstructured":"Kroger N, Holler E, Kobbe G. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009; 114(26):5264-5270.","DOI":"10.1182\/blood-2009-07-234880"},{"key":"49643","doi-asserted-by":"crossref","unstructured":"Patriarca F, Masciulli A, Bacigalupo A. Busulfan- or thiotepa-based conditioning in myelofibrosis: a phase II multicenter randomized study from the GITMO Group. Biol Blood Marrow Transplant. 2019; 25(5):932-940.","DOI":"10.1016\/j.bbmt.2018.12.064"},{"key":"49644","doi-asserted-by":"crossref","unstructured":"Shanavas M, Popat U, Michaelis LC. Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1\/2 inhibitors. Biol Blood Marrow Transplant. 2016; 22(3):432-440.","DOI":"10.1016\/j.bbmt.2015.10.005"},{"key":"49645","doi-asserted-by":"crossref","unstructured":"Kr\u00f6ger N, Sbianchi G, Sirait T. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Leukemia. 2021; 35(12):3551-3560.","DOI":"10.1038\/s41375-021-01276-4"},{"key":"49646","doi-asserted-by":"crossref","unstructured":"Gagelmann N, Ditschkowski M, Bogdanov R. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood. 2019; 133(20):2233-2242.","DOI":"10.1182\/blood-2018-12-890889"},{"key":"49647","doi-asserted-by":"crossref","unstructured":"Tamari R, Rapaport F, Zhang N. Impact of high-molecular-risk mutations on transplantation outcomes in patients with myelofibrosis. Biol Blood Marrow Transplant. 2019; 25(6):1142-1151.","DOI":"10.1016\/j.bbmt.2019.01.002"},{"key":"49648","unstructured":"Przepiorka D, Weisdorf D, Martin P. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15(6):825-828."},{"key":"49649","doi-asserted-by":"crossref","unstructured":"Sullivan KM, Shulman HM, Storb R. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981; 57(2):267-276.","DOI":"10.1182\/blood.V57.2.267.bloodjournal572267"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281958\/75331","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281958\/75780","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10975\/75331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:29Z","timestamp":1794045809000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.281958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.281958","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,9]]}}}